Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3978) 3978
Publication (256) 256
Book Review (96) 96
Newsletter (86) 86
Newspaper Article (52) 52
Book Chapter (15) 15
Magazine Article (11) 11
Trade Publication Article (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adalimumab (3469) 3469
humans (2903) 2903
index medicus (2389) 2389
infliximab (1936) 1936
female (1797) 1797
male (1685) 1685
adult (1408) 1408
middle aged (1372) 1372
etanercept (1262) 1262
tumor necrosis factor-alpha - antagonists & inhibitors (1250) 1250
treatment outcome (1199) 1199
rheumatoid arthritis (997) 997
rheumatology (982) 982
antibodies, monoclonal - therapeutic use (875) 875
arthritis, rheumatoid - drug therapy (873) 873
antibodies, monoclonal, humanized (719) 719
antirheumatic agents - therapeutic use (714) 714
therapy (706) 706
aged (694) 694
psoriasis (656) 656
drug therapy (653) 653
dermatology (624) 624
care and treatment (622) 622
gastroenterology & hepatology (582) 582
efficacy (576) 576
rheumatoid-arthritis (565) 565
double-blind (552) 552
antibodies, monoclonal, humanized - therapeutic use (541) 541
methotrexate (533) 533
arthritis (519) 519
dosage and administration (513) 513
severity of illness index (490) 490
safety (477) 477
antibodies, monoclonal - adverse effects (473) 473
pharmacology & pharmacy (473) 473
crohn disease - drug therapy (467) 467
crohn's disease (453) 453
tumor necrosis factor (446) 446
psoriasis - drug therapy (445) 445
antibodies, monoclonal - administration & dosage (444) 444
retrospective studies (421) 421
young adult (419) 419
antirheumatic agents - adverse effects (415) 415
anti-inflammatory agents - therapeutic use (408) 408
crohns-disease (403) 403
adalimumab - therapeutic use (401) 401
antirheumatic agents - administration & dosage (393) 393
medicine & public health (386) 386
inflammatory-bowel-disease (385) 385
tumor necrosis factor-tnf (379) 379
analysis (378) 378
drug therapy, combination (368) 368
immunoglobulin g - therapeutic use (365) 365
receptors, tumor necrosis factor - therapeutic use (359) 359
monoclonal antibodies (358) 358
adolescent (344) 344
risk factors (337) 337
patients (325) 325
inflammatory bowel disease (320) 320
research (313) 313
antibodies, monoclonal, humanized - administration & dosage (306) 306
antibodies, monoclonal, humanized - adverse effects (305) 305
rheumatoid factor (298) 298
adalimumab - administration & dosage (296) 296
ulcerative colitis (294) 294
drug administration schedule (293) 293
time factors (284) 284
disease (278) 278
follow-up studies (277) 277
immunology (276) 276
anti-inflammatory agents - administration & dosage (273) 273
clinical trials (273) 273
complications and side effects (259) 259
dose-response relationship, drug (258) 258
trial (247) 247
methotrexate - therapeutic use (242) 242
certolizumab pegol (237) 237
abridged index medicus (236) 236
remission induction (235) 235
monoclonal-antibody (232) 232
double-blind method (231) 231
remission (226) 226
placebo-controlled trial (221) 221
anti-inflammatory agents - adverse effects (219) 219
prospective studies (219) 219
internal medicine (217) 217
health aspects (215) 215
immunosuppressive agents - therapeutic use (213) 213
infliximab - therapeutic use (213) 213
antibodies (212) 212
studies (206) 206
adalimumab - adverse effects (205) 205
tumor necrosis factor-alpha - immunology (203) 203
patient outcomes (202) 202
biologics (201) 201
medical research (201) 201
quality of life (201) 201
inflammation (200) 200
necrosis-factor-alpha (198) 198
tnf inhibitors (194) 194
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3963) 3963
German (43) 43
French (33) 33
Spanish (29) 29
Japanese (18) 18
Russian (13) 13
Hungarian (11) 11
Korean (11) 11
Italian (7) 7
Danish (4) 4
Polish (2) 2
Turkish (2) 2
Arabic (1) 1
Chinese (1) 1
Croatian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality
by Ingram, J.R and Woo, P.N and Chua, S.L and Ormerod, A.D and Desai, N and Kai, A.C and Hood, K and Burton, T and Kerdel, F and Garner, S.E and Piguet, V
British Journal of Dermatology, ISSN 0007-0963, 05/2016, Volume 174, Issue 5, pp. 970 - 978
Summary More than 50 interventions have been used to treat hidradenitis suppurativa (HS), and so therapy decisions can be challenging. Our objective was to... 
CLINDAMYCIN | MODERATE | THERAPY | CONTROLLED CROSSOVER TRIAL | ADALIMUMAB | ALUMINUM-GARNET LASER | DOUBLE-BLIND | RANDOMIZED-TRIAL | DERMATOLOGY | Norgestrel - administration & dosage | Wound Closure Techniques | Etanercept - administration & dosage | Administration, Oral | Cyproterone Acetate - administration & dosage | Dermatologic Agents - administration & dosage | Humans | Hidradenitis Suppurativa - drug therapy | Treatment Outcome | Gentamicins - administration & dosage | Infliximab - administration & dosage | Adalimumab - administration & dosage | Clindamycin - administration & dosage | Quality of Life | Adult | Androgen Antagonists - administration & dosage | Ethinyl Estradiol - administration & dosage | Anti-Bacterial Agents - administration & dosage | Systematic Review | Reviews
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Tofacitinib versus Methotrexate in Rheumatoid Arthritis
by Lee, Eun Bong and Fleischmann, Roy and Hall, Stephen and Wilkinson, Bethanie and Bradley, John D and Gruben, David and Koncz, Tamas and Krishnaswami, Sriram and Wallenstein, Gene V and Zang, Chuanbo and Zwillich, Samuel H and van Vollenhoven, Ronald F and ORAL Start Investigators
The New England Journal of Medicine, ISSN 0028-4793, 06/2014, Volume 370, Issue 25, pp. 2377 - 2386
In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and... 
MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | ADALIMUMAB | RECOMMENDATIONS | COMBINATION THERAPY | JOINT DAMAGE | DISEASE | PLUS METHOTREXATE | DOUBLE-BLIND | ETANERCEPT | CP-690,550 | Herpes Zoster - etiology | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - blood | Cholesterol - blood | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Arthritis, Rheumatoid - complications | Dose-Response Relationship, Drug | Janus Kinase 3 - antagonists & inhibitors | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Piperidines - administration & dosage | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Methotrexate - adverse effects | Protein Kinase Inhibitors - administration & dosage | Piperidines - adverse effects | Pyrimidines - adverse effects | Creatinine - blood | Methotrexate - administration & dosage | Care and treatment | Dosage and administration | Tofacitinib | Comparative analysis | Methotrexate | Rheumatoid arthritis | Creatinine | Herpes zoster | C-reactive protein | Kinases | Joint diseases | E.S.R | Lymphoma | Sedimentation | Cholesterol | Pain | Rheumatism | Janus kinase | Drug therapy | Pharmaceuticals | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
by Fleischmann, Roy, Prof and Mysler, Eduardo, MD and Hall, Stephen, MD and Kivitz, Alan J, MD and Moots, Robert J, Prof and Luo, Zhen, PhD and DeMasi, Ryan, MD and Soma, Koshika, MD and Zhang, Richard, PhD and Takiya, Liza, PharmD and Tatulych, Svitlana, MD and Mojcik, Christopher, MD and Krishnaswami, Sriram, PhD and Menon, Sujatha, PhD and Smolen, Josef S, Prof and ORAL Strategy Investigators and ORAL Strategy investigators
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10093, pp. 457 - 468
Summary Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | NECROSIS-FACTOR | PLACEBO | JANUS KINASE INHIBITOR | INADEQUATE RESPONSE | LONG-TERM SAFETY | PLUS METHOTREXATE | AMERICAN-COLLEGE | OPEN-LABEL | COMBINATION | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Adalimumab - adverse effects | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Piperidines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Treatment Outcome | Methotrexate - adverse effects | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Methotrexate - administration & dosage | Rheumatoid factor | Care and treatment | Analysis | Clinical trials | Arthritis | Pharmaceutical industry | Methotrexate | Rheumatology | Patients | Studies | Rheumatoid arthritis | Monoclonal antibodies | Rheumatism | TNF inhibitors | Janus kinase | Tumor necrosis factor-TNF | Safety | Drug therapy | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Dosing down with biologic therapies: a systematic review and clinicians' perspective
by Edwards, Christopher J and Fautrel, Bruno and Schulze-Koops, Hendrik and Huizinga, Tom W J and Kruger, Klaus
Rheumatology (Oxford, England), ISSN 1462-0324, 11/2017, Volume 56, Issue 11, pp. 1847 - 1856
The effectiveness of biologic therapies now means that remission or low disease activity are realistic targets for treatment. However, after achieving... 
dosing down | dose spacing | biologic therapy | dose tapering | treatment withdrawal | psoriatic arthritis | systematic review | axial spondyloarthritis | rheumatoid arthritis | TARGET RECOMMENDATIONS | ANKYLOSING-SPONDYLITIS | RHEUMATOLOGY | ADALIMUMAB PLUS METHOTREXATE | PSORIATIC-ARTHRITIS | RHEUMATOID-ARTHRITIS PATIENTS | DISCONTINUATION | LOW DISEASE-ACTIVITY | DOSE REDUCTION | INFLIXIMAB | REMISSION | Spondylarthropathies - drug therapy | Etanercept - administration & dosage | Antirheumatic Agents - administration & dosage | Humans | Remission Induction | Infliximab - administration & dosage | Abatacept - administration & dosage | Rituximab - administration & dosage | Adalimumab - administration & dosage | Antibodies, Monoclonal - administration & dosage | Arthritis, Rheumatoid - drug therapy | Arthritis, Psoriatic - drug therapy | Maintenance Chemotherapy | Biological Products - administration & dosage | Certolizumab Pegol - administration & dosage | Reviews
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
by Warren, Richard B and Smith, Catherine H and Yiu, Zenas Z.N and Ashcroft, Darren M and Barker, Jonathan N.W.N and Burden, A. David and Lunt, Mark and McElhone, Kathleen and Ormerod, Anthony D and Owen, Caroline M and Reynolds, Nick J and Griffiths, Christopher E.M and BADBIR Study Grp
Journal of Investigative Dermatology, ISSN 0022-202X, 11/2015, Volume 135, Issue 11, pp. 2632 - 2640
Drug survival reflects a drug’s effectiveness, safety, and tolerability. We assessed the drug survival of biologics used to treat psoriasis in a prospective... 
RATES | IMPACT | ADALIMUMAB | USTEKINUMAB | PERSISTENCE | PREDICTORS | BODY-MASS INDEX | GENDER | RISK | ETANERCEPT | DERMATOLOGY | Biological Therapy - methods | Prospective Studies | Biological Products - pharmacokinetics | Etanercept - administration & dosage | Humans | Middle Aged | Psoriasis - diagnosis | Male | Infliximab - administration & dosage | Infliximab - pharmacokinetics | Dose-Response Relationship, Drug | Societies, Medical | Etanercept - pharmacokinetics | Adult | Female | Registries | Ustekinumab - administration & dosage | Psoriasis - drug therapy | Drug Administration Schedule | Dermatology | Kaplan-Meier Estimate | Proportional Hazards Models | Maximum Tolerated Dose | Adalimumab - administration & dosage | Ustekinumab - pharmacokinetics | Biological Products - administration & dosage | Cohort Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
by Khanna, Reena, MD and Bressler, Brian, Prof and Levesque, Barrett G, MD and Zou, Guangyong, Prof and Stitt, Larry W, MSc and Greenberg, Gordon R, Prof and Panaccione, Remo, Prof and Bitton, Alain, Prof and Paré, Pierre, Prof and Vermeire, Séverine, Prof and D'Haens, Geert, Prof and MacIntosh, Donald, Prof and Sandborn, William J, Prof and Donner, Allan, Prof and Vandervoort, Margaret K, MSc and Morris, Joan C, MHSc and Feagan, Brian G, Prof and REACT Study Investigators
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10006, pp. 1825 - 1834
Summary Background Conventional management of Crohn's disease features incremental use of therapies. However, early combined immunosuppression (ECI), with a... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | EUROQOL | SCORE | VALIDATION | QUALITY-OF-LIFE | INDEX | INFLIXIMAB | SEVERITY | HEALTH SURVEY | SF-36 | Azathioprine - administration & dosage | Azathioprine - therapeutic use | Immunosuppression - methods | Humans | Mercaptopurine - administration & dosage | Male | Treatment Outcome | Methotrexate - therapeutic use | Antimetabolites - therapeutic use | Infliximab - therapeutic use | Infliximab - administration & dosage | Antimetabolites - administration & dosage | Crohn Disease - therapy | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Mercaptopurine - therapeutic use | Adult | Female | Methotrexate - administration & dosage | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Clinical trials | Gastrointestinal diseases | Immunotherapy | Algorithms | Surgery | Mortality | Gastroenterology | Drug therapy | Crohns disease | Quality of life
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration? A STROBE-compliant retrospective cohort study
by Otake, Haruka and Matsumoto, Satohiro and Mashima, Hirosato
Medicine (United States), ISSN 0025-7974, 2017, Volume 96, Issue 16, p. e6635
Although biologics are important inflammatory bowel disease therapies, loss of response (LOR) remains problematic. We evaluated LOR to biologics in our Crohn... 
Crohn disease | Loss of response | Infliximab | Adalimumab | CROHNS-DISEASE | infliximab | SECONDARY LOSS | adalimumab | TRIAL | DOSE INTENSIFICATION | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | loss of response | REMISSION | REQUIREMENT | ESCALATION | Humans | Middle Aged | Drug Tolerance | Male | Infliximab - therapeutic use | Young Adult | Adalimumab - therapeutic use | C-Reactive Protein - metabolism | Crohn Disease - drug therapy | Adolescent | Age of Onset | Gastrointestinal Agents - therapeutic use | Adult | Female | Aged | Retrospective Studies | Usage | Inflammatory bowel diseases | Care and treatment | Dosage and administration | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
by Ports, W.C and Khan, S and Lan, S and Lamba, M and Bolduc, C and Bissonnette, R and Papp, K
British Journal of Dermatology, ISSN 0007-0963, 07/2013, Volume 169, Issue 1, pp. 137 - 145
Summary Background Tofacitinib (CP‐690,550) is a novel Janus kinase inhibitor in development as an oral formulation for the treatment of several inflammatory... 
PLACEBO | MONOTHERAPY | ADALIMUMAB | PATHWAY | ACTIVE RHEUMATOID-ARTHRITIS | INADEQUATE RESPONSE | DOUBLE-BLIND | METHOTREXATE | COMBINATION | CP-690,550 | DERMATOLOGY | Pyrroles - pharmacokinetics | Dermatologic Agents - administration & dosage | Humans | Middle Aged | Male | Administration, Cutaneous | Protein Kinase Inhibitors - adverse effects | Dermatologic Agents - adverse effects | Young Adult | Pyrroles - administration & dosage | Pyrroles - adverse effects | Adult | Female | Piperidines - pharmacokinetics | Ointments | Protein Kinase Inhibitors - pharmacokinetics | Piperidines - administration & dosage | Psoriasis - drug therapy | Double-Blind Method | Drug Administration Schedule | Pyrimidines - administration & dosage | Treatment Outcome | Protein Kinase Inhibitors - administration & dosage | Piperidines - adverse effects | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Dermatologic Agents - pharmacokinetics | Chronic Disease | Psoriasis | Dermatology | Formulae, receipts, prescriptions | Clinical trials | Mutual fund industry | Dermatologic agents | Drug therapy | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Impact of Biologic Agents With and Without Concomitant Methotrexate and at Reduced Doses in Older Rheumatoid Arthritis Patients
by Zhang, Jie and Xie, Fenglong and Delzell, Elizabeth and Yun, Huifeng and Lewis, James D and Haynes, Kevin and Chen, Lang and Beukelman, Timothy and Saag, Kenneth G and Curtis, Jeffrey R
Arthritis Care & Research, ISSN 2151-464X, 05/2015, Volume 67, Issue 5, pp. 624 - 632
Objective To examine whether concomitant methotrexate (MTX) use is associated with better biologic persistence and whether self‐administered anti–tumor... 
CLAIMS DATA | ANTIBODIES | IMMUNOGENICITY | CROHNS-DISEASE | ADALIMUMAB TREATMENT | DOUBLE-BLIND | RANDOMIZED CONTROLLED-TRIAL | RHEUMATOLOGY | ETANERCEPT | INFLIXIMAB | CLINICAL-RESPONSE | Age Factors | Antirheumatic Agents - administration & dosage | United States | Humans | Male | Self Administration | Antibodies, Monoclonal, Humanized - administration & dosage | Etanercept | Infliximab | Time Factors | Arthritis, Rheumatoid - drug therapy | Female | Retrospective Studies | Drug Therapy, Combination | Arthritis, Rheumatoid - diagnosis | Databases, Factual | Drug Administration Schedule | Medicare | Kaplan-Meier Estimate | Proportional Hazards Models | Receptors, Tumor Necrosis Factor - administration & dosage | Treatment Outcome | Immunoglobulin G - administration & dosage | Injections | Antibodies, Monoclonal - administration & dosage | Methotrexate - administration & dosage | Aged | Biological Products - administration & dosage | Adalimumab | Arthritis, Rheumatoid - immunology | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study
by Fagerli, Karen Minde and Lie, Elisabeth and van der Heijde, Désirée and Heiberg, Marte Schrumpf and Lexberg, Åse Stavland and Rødevand, Eric and Kalstad, Synøve and Mikkelsen, Knut and Kvien, Tore K
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2014, Volume 73, Issue 1, pp. 132 - 137
Background The role of co-medication with tumour necrosis factor inhibitors (TNFi) is well established in rheumatoid arthritis and ankylosing spondylitis. In... 
RHEUMATOID-ARTHRITIS | CONTROLLED-TRIAL | EFFICACY | TNF-alpha | SAFETY | ANKYLOSING-SPONDYLITIS | RHEUMATOLOGY | RECOMMENDATIONS | DOUBLE-BLIND | THERAPIES | Methotrexate | ETANERCEPT | INFLIXIMAB | Psoriatic Arthritis | Antirheumatic Agents - administration & dosage | Humans | Methotrexate - pharmacokinetics | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Antibodies, Monoclonal, Humanized - administration & dosage | Etanercept | Infliximab | Antibodies, Monoclonal, Humanized - pharmacokinetics | Arthritis, Psoriatic - drug therapy | Antirheumatic Agents - adverse effects | Adult | Female | Drug Therapy, Combination | Receptors, Tumor Necrosis Factor - metabolism | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal - pharmacokinetics | Receptors, Tumor Necrosis Factor - administration & dosage | Treatment Outcome | Immunoglobulin G - administration & dosage | Immunoglobulin G - adverse effects | Methotrexate - adverse effects | Antibodies, Monoclonal - administration & dosage | Antirheumatic Agents - pharmacokinetics | Methotrexate - administration & dosage | Adalimumab | Longitudinal Studies | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Immunoglobulin G - metabolism | Usage | Dosage and administration | Drug therapy | Tumor necrosis factor inhibitors | Psoriatic arthritis | Studies | Variables | Immunoglobulins | Rheumatology | TNF inhibitors | Arthritis | Regression analysis | Multivariate analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights